UNDERSTANDING AND ADDRESSING NEUROPATHY
ABRAXANE PHASE III MBC TRIAL

71% of 229 patients who received ABRAXANE developed Grades 1-3 sensory neuropathy (no Grade 4 was reported)
ABRAXANE® for metastatic breast cancer (MBC) - Grade 3 neuropathy from the phase III trial: 10% of patients developed Grade 3 neuropathy, 22 days median time to documented improvement for 14 of the 24 patients with Grade 3 neuropathy. Of the 10 patients without documented improvement, 4 discontinued due to peripheral neuropathy. 42% of patients resumed ABRAXANE® at a reduced dose - chart ABRAXANE® for metastatic breast cancer (MBC) - Grade 3 neuropathy from the phase III trial: 10% of patients developed Grade 3 neuropathy, 22 days median time to documented improvement for 14 of the 24 patients with Grade 3 neuropathy. Of the 10 patients without documented improvement, 4 discontinued due to peripheral neuropathy. 42% of patients resumed ABRAXANE® at a reduced dose - chart
  • The frequency and severity of sensory neuropathy increased with cumulative doses of ABRAXANE
    • 3% of patients (7/229) discontinued treatment with ABRAXANE due to sensory neuropathy
  • Only 1 incident of motor neuropathy (Grade 2) was observed in either arm of the controlled trial
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL